# A Study to Test How Well Different Doses of BI 3706674 Are Tolerated by People With Advanced Cancer in the Stomach and Oesophagus

> **NCT06056024** · PHASE1 · COMPLETED · sponsor: **Boehringer Ingelheim** · enrollment: 47 (actual)

## Conditions studied

- Solid Tumor, KRAS Mutation

## Interventions

- **DRUG:** BI 3706674

## Key facts

- **NCT ID:** NCT06056024
- **Lead sponsor:** Boehringer Ingelheim
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2023-12-06
- **Primary completion:** 2025-12-17
- **Final completion:** 2025-12-17
- **Target enrollment:** 47 (ACTUAL)
- **Last updated:** 2026-03-17


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06056024

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06056024, "A Study to Test How Well Different Doses of BI 3706674 Are Tolerated by People With Advanced Cancer in the Stomach and Oesophagus". Retrieved via AI Analytics 2026-07-28 from https://api.ai-analytics.org/clinical/NCT06056024. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*